|
ERAS
|
Erasca, Inc
|
US
|
NASDAQ
|
|
ERYP
|
Erytech Pharma S.A.
|
US
|
NASDAQ
|
|
ESPR
|
Esperion Therapeutics, Inc.
|
US
|
NASDAQ
|
|
ETNB
|
89bio, Inc.
|
US
|
NASDAQ
|
|
EVFM
|
Evofem Biosciences, Inc.
|
US
|
NASDAQ
|
|
EWTX
|
Edgewise Therapeutics, Inc.
|
US
|
NASDAQ
|
|
EYPT
|
EyePoint Pharmaceuticals, Inc.
|
US
|
NASDAQ
|
|
FATE
|
Fate Therapeutics, Inc.
|
US
|
NASDAQ
|
|
FBIO
|
Fortress Biotech, Inc.
|
US
|
NASDAQ
|
|
FBIOP
|
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
|
US
|
NASDAQ
|
|
FENC
|
Fennec Pharmaceuticals Inc.
|
US
|
NASDAQ
|
|
FGEN
|
FibroGen, Inc
|
US
|
NASDAQ
|
|
FMTX
|
Forma Therapeutics Holdings, Inc.
|
US
|
NASDAQ
|
|
FNCH
|
Finch Therapeutics Group, Inc.
|
US
|
NASDAQ
|
|
FOLD
|
Amicus Therapeutics, Inc.
|
US
|
NASDAQ
|
|
FSTX
|
F-star Therapeutics, Inc.
|
US
|
NASDAQ
|
|
FULC
|
Fulcrum Therapeutics, Inc.
|
US
|
NASDAQ
|
|
FWBI
|
First Wave BioPharma, Inc.
|
US
|
NASDAQ
|
|
FWP
|
Forward Pharma A/S
|
US
|
NASDAQ
|
|
GH
|
Guardant Health, Inc.
|
US
|
NASDAQ
|